JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D III Year PHARMACOTHERAPEUTICS - II Previous Question Paper (October - 2020 - R08)

The management of Urinary Tract Infections (UTIs) focuses on eradicating the causative pathogen, relieving symptoms, and preventing recurrence. Empirical antibiotic therapy is initiated based on local resistance patterns, commonly using nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin for uncomplicated cystitis. For complicated UTIs or pyelonephritis, fluoroquinolones or intravenous cephalosporins are preferred. Treatment duration typically ranges from 3 days for uncomplicated cases to 7–14 days for pyelonephritis. Supportive care includes adequate hydration and analgesics like phenazopyridine for dysuria. In recurrent infections, lifestyle modifications such as increased fluid intake, post-coital voiding, and occasionally low-dose prophylactic antibiotics are employed.

Peripheral dialysis, commonly referred to as peritoneal dialysis, is a renal replacement therapy that utilizes the peritoneum as a semi-permeable membrane to filter waste products and excess fluid from the blood. The process involves the infusion of a sterile dialysis solution (dialysate) into the peritoneal cavity via a permanent catheter. Through the principles of osmosis and diffusion, metabolic waste products like urea and creatinine, along with excess electrolytes, move from the blood vessels in the peritoneal lining into the dialysate. After a specified dwell time, the fluid containing the waste is drained and replaced with fresh solution. This modality allows for continuous or intermittent treatment, offering patients greater independence compared to hemodialysis, though it carries a risk of peritonitis, which requires strict aseptic technique during exchange procedures.

Rational use of antibiotics ensures optimal clinical outcomes while minimizing the emergence of antimicrobial resistance. Key guidelines include: 1) Establishing a definitive diagnosis before initiating therapy; 2) Selecting the most narrow-spectrum agent effective against the identified pathogen; 3) Utilizing appropriate dosing, frequency, and duration of therapy based on pharmacokinetic and pharmacodynamic principles; 4) De-escalating therapy once culture and sensitivity results are available; 5) Avoiding prophylactic use unless clinically indicated; and 6) Adhering to institutional antibiograms to guide empirical choices.

The management of tuberculosis (TB) follows a standardized regimen divided into an intensive phase and a continuation phase to ensure complete eradication of the bacilli. The standard first-line treatment for drug-susceptible pulmonary TB consists of a 6-month regimen: the intensive phase (2 months) involves four drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E). This is followed by the continuation phase (4 months) using Isoniazid and Rifampicin.

Key aspects of management include:

• Monitoring: Regular assessment of liver function tests is essential due to the hepatotoxic potential of Isoniazid, Rifampicin, and Pyrazinamide.
• Adherence: Directly Observed Treatment, Short-course (DOTS) is the gold standard strategy to ensure patient compliance and prevent the development of multidrug-resistant TB (MDR-TB).
• Nutritional Support: Patients require adequate nutrition to support immune function during the prolonged treatment period.
• Follow-up: Sputum smear microscopy or culture is performed at the end of the intensive phase and at the end of treatment to confirm conversion to negative status.
• Special Considerations: Patients with HIV co-infection, renal impairment, or pregnancy require adjusted regimens and careful monitoring for drug-drug interactions, particularly with antiretroviral therapy.